{"altmetric_id":2652803,"counts":{"readers":{"mendeley":26,"citeulike":0,"connotea":0},"news":{"unique_users_count":1,"unique_users":["bioportfolio"],"posts_count":1},"total":{"posts_count":1}},"citation":{"abstract":"Abstract Purpose: Unresectable chest wall recurrences of breast cancer (CWR) in heavily pretreated patients are especially difficult to treat. We hypothesised that thermally enhanced drug delivery using low temperature liposomal doxorubicin (LTLD), given with mild local hyperthermia (MLHT), will be safe and effective in this population.","abstract_source":"pubmed","altmetric_jid":"4f6fa5293cf058f610003e50","authors":["Zagar TM","Vujaskovic Z","Formenti S","Rugo H","Muggia F","O'Connor B","Myerson R","Stauffer P","Hsu IC","Diederich C","Straube W","Boss MK","Boico A","Craciunescu O","Maccarini P","Needham D","Borys N","Blackwell KL","Dewhirst MW","Timothy M. Zagar","Zeljko Vujaskovic","Silvia Formenti","Hope Rugo","Franco Muggia","Brigid O\u2019Connor","Robert Myerson","Paul Stauffer","I-Chow Hsu","Chris Diederich","William Straube","Mary-Keara Boss","Alina Boico","Oana Craciunescu","Paolo Maccarini","David Needham","Nicholas Borys","Kimberly L. Blackwell","Mark W. Dewhirst"],"doi":"10.3109\/02656736.2014.936049","endpage":"294","first_seen_on":"2014-09-04T20:01:00+00:00","funders":["nci"],"issns":["0265-6736","1464-5157"],"issue":"5","journal":"International Journal of Hyperthermia","last_mentioned_on":1409822703,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25144817"],"pmid":"25144817","pubdate":"2014-08-23T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Life Sciences","Medicine","Health Sciences","Health Professions","Biochemistry, Genetics and Molecular Biology"],"startpage":"285","subjects":["neoplasms"],"title":"Two phase I dose-escalation\/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.","type":"article","uri":"http:\/\/www.tandfonline.com\/doi\/full\/10.3109\/02656736.2014.936049","volume":"30","mendeley_url":"http:\/\/www.mendeley.com\/research\/two-phase-i-doseescalationpharmacokinetics-studies-low-temperature-liposomal-doxorubicin-ltld-mild-l"},"altmetric_score":{"score":7,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":4216710,"mean":5.1296613826895,"rank":528506,"this_scored_higher_than_pct":86,"this_scored_higher_than":3664152,"rank_type":"exact","sample_size":4216710,"percentile":86},"similar_age_3m":{"total_number_of_other_articles":110056,"mean":8.2302641951752,"rank":17884,"this_scored_higher_than_pct":82,"this_scored_higher_than":91145,"rank_type":"exact","sample_size":110056,"percentile":82},"this_journal":{"total_number_of_other_articles":88,"mean":2.578367816092,"rank":7,"this_scored_higher_than_pct":90,"this_scored_higher_than":80,"rank_type":"exact","sample_size":88,"percentile":90},"similar_age_this_journal_3m":{"total_number_of_other_articles":7,"mean":1,"rank":1,"this_scored_higher_than_pct":85,"this_scored_higher_than":6,"rank_type":"exact","sample_size":7,"percentile":85}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":4,"Researcher":5,"Student  > Ph. D. Student":5,"Student  > Postgraduate":1,"Student  > Master":6,"Other":3,"Professor":2},"by_discipline":{"Engineering":2,"Medicine and Dentistry":9,"Chemistry":1,"Physics and Astronomy":2,"Agricultural and Biological Sciences":4,"Biochemistry, Genetics and Molecular Biology":1,"Mathematics":1,"Unspecified":3,"Pharmacology, Toxicology and Pharmaceutical Science":3}}}},"posts":{"news":[{"title":"Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox\u00c2 in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia","url":"http:\/\/www.bioportfolio.com\/news\/article\/2053388\/Celsion-Reports-Consolidated-Duke-University-and-Celsions-DIGNITY-Study-Clinical-Data-on.html","license":"public","citation_ids":[2652803],"posted_on":"2014-09-04T09:25:03+00:00","summary":"LAWRENCEVILLE N.J. Sept. 4 2014 PRNewswire &160;September 4 2014 PRNewswire &160;Celsion Corporation NASDAQ CLSN today announced that data from two Phase I studies on ThermoDox&174; in recurrent chest wall breast cancer were published in the In...","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}}]}}